These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25495659)

  • 1. Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic end-stage renal disease patients.
    Barbagallo CM; Noto D; Cefalù AB; Ganci A; Giammarresi C; Panno D; Cusumano G; Greco M; Di Gaudio F; Averna MR
    Hemodial Int; 2015 Jul; 19(3):360-7. PubMed ID: 25495659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.
    Shoji T; Nishizawa Y; Kawagishi T; Tanaka M; Kawasaki K; Tabata T; Inoue T; Morii H
    Atherosclerosis; 1997 Jun; 131(2):229-36. PubMed ID: 9199276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherogenic lipoproteins in end-stage renal disease.
    Shoji T; Ishimura E; Inaba M; Tabata T; Nishizawa Y
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S30-3. PubMed ID: 11576918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study.
    Dusejovska M; Stankova B; Vecka M; Rychlíkova J; Mokrejsova M; Rychlík I; Zak A
    Curr Vasc Pharmacol; 2018; 16(3):298-305. PubMed ID: 28554308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid and lipoprotein metabolism in chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.
    Vaziri ND; Navab K; Gollapudi P; Moradi H; Pahl MV; Barton CH; Fogelman AM; Navab M
    J Natl Med Assoc; 2011 Jun; 103(6):524-33. PubMed ID: 21830637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure.
    Sentí M; Romero R; Pedro-Botet J; Pelegrí A; Nogués X; Rubiés-Prat J
    Kidney Int; 1992 May; 41(5):1394-9. PubMed ID: 1614054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skew of plasma low- and high-density lipoprotein distributions to less dense subfractions in normotriglyceridemic chronic kidney disease patients on maintenance hemodialysis treatment.
    Homma K; Homma Y; Shiina Y; Wakino S; Suzuki M; Fujishima S; Hayashi K; Hori S; Itoh H
    Nephron Clin Pract; 2013; 123(1-2):41-5. PubMed ID: 23752220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein heterogeneity in end-stage renal disease.
    Joven J; Vilella E; Ahmad S; Cheung MC; Brunzell JD
    Kidney Int; 1993 Feb; 43(2):410-8. PubMed ID: 8441237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.
    Tani S; Matsumoto M; Nagao K; Hirayama A
    J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [When lipids increase in dialysis: the role of heparin! Standard heparin increases, low-molecular-weight heparin lowers triglycerides].
    Wiemer J; Scherberich JE
    MMW Fortschr Med; 1999 Oct; 141(43):29-32. PubMed ID: 10912118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.
    Quaschning T; Krane V; Metzger T; Wanner C
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S14-9. PubMed ID: 11576915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease.
    Barbagallo CM; Rizzo M; Noto D; Frasheri A; Pernice V; Rubino A; Pieri D; Pinto V; Cefalù AB; Giordano C; Notarbartolo A; Averna MR
    Metabolism; 2006 May; 55(5):662-8. PubMed ID: 16631444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
    Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
    Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index.
    Coimbra S; Reis F; Nunes S; Viana S; Valente MJ; Rocha S; Catarino C; Rocha-Pereira P; Bronze-da-Rocha E; Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Belo L; Santos-Silva A
    Oxid Med Cell Longev; 2019; 2019():3021785. PubMed ID: 30911344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.
    Lee DM; Knight-Gibson C; Samuelsson O; Attman PO; Wang CS; Alaupovic P
    Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.
    Wasan KM; Sivak O; Cote RA; MacInnes AI; Boulanger KD; Lynn M; Christ WJ; Hawkins LD; Rossignol DP
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2796-803. PubMed ID: 12936976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
    Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K
    Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis.
    O'Neal D; Lee P; Murphy B; Best J
    Am J Kidney Dis; 1996 Jan; 27(1):84-91. PubMed ID: 8546142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.